Vision and

focus

Aleksandra Rizo, M.D., Ph.D., joined Vividion in 2022 as President and Head of Research and Development. In 2023 Dr. Rizo was promoted to President and Chief Executive Officer and joined the Board of Directors of Vividion.

Previously, Dr. Rizo served as Executive Vice President and Chief Medical Officer of Geron Corporation where she provided leadership and direction for all clinical and translational efforts. Included in her reporting responsibilities were clinical development, clinical operations, clinical pharmacology, biometrics, translational research, program management, and medical affairs. Prior to joining Geron, Dr. Rizo was Strategy and Clinical Lead at Celgene Corporation where she led submission activities which resulted in successful NDA and MAA approvals and participated in strategic development activities in the Myeloid Therapeutic area. From 2008 to 2018, Dr. Rizo served in a number of oncology drug development functions with increasing responsibilities at Janssen Research and Development, LLC (Janssen), including Senior Director, Compound Development Team Leader for the myeloid portfolio and Senior Director, Global Clinical Leader for multiple assets, including imetelstat, ibrutinib mantle cell lymphoma (MCL), and others. In these roles, she had oversight and leadership responsibilities for clinical development strategy, execution, and regulatory submission activities. In addition, Dr. Rizo was a core member of Janssen’s Hematology Strategy Team where she participated and led multiple diligence projects.

Dr. Rizo earned an M.D. from the University Ss Cyril and Methodius, Skopje, Macedonia, where she also completed a residency in internal medicine/hematology. Dr. Rizo obtained her Ph.D. in stem cell biology from the University of Groningen in the Netherlands and the University of Tokyo, in Japan.

Jenna Goldberg, M.D., joined Vividion in 2022 as Chief Medical Officer. In this capacity she is responsible for oversight, strategy, and execution of Vividion’s clinical programs. She oversees the clinical development, clinical operations, clinical biomarkers, and biometrics departments.

Prior to Dr. Goldberg’s move to Vividion, she was Vice President, Early Clinical Development at Janssen Research and Development. In this role, she had increasing responsibilities and supervised clinical efforts for all Phase 1 studies in the myeloma, cellular therapy, clinical pharmacology, and prostate cancer disease spaces. Notably, Dr. Goldberg supervised protocol developments, successful IND submissions of numerous compounds, and all early development (ED) clinical efforts for teclistamab, talquetamab, and ciltacabtagene autoleucel, that are all currently approved medicines following Breakthrough Therapy Designation. In this position, she worked closely with critical functions including translational research, clinical pharmacology, regulatory, and statistics. Prior to joining Early Development, Dr. Goldberg was Medical Director on the ibrutinib program at Janssen where she worked on registration studies for relapsed/refractory and frontline mantle cell lymphoma.

Before joining industry, Dr. Goldberg was an Assistant Attending Physician at Memorial Hospital/Assistant Member of Memorial Sloan-Kettering Cancer Center where she served on the Adult Bone Marrow Transplant Service after completion of her fellowship there. She earned an M.D. degree from the Johns Hopkins School of Medicine and a B.S. degree in biology from the Massachusetts Institute of Technology.

Matt Patricelli, Ph.D., joined Vividion in 2016 as a Founding Scientist and member of the company’s Senior Management Team, and has taken on increasing responsibility since that time. He was promoted to Chief Scientific Officer in 2023 and currently leads all aspects of discovery and preclinical research at Vividion. In this role he oversees the Early Discovery and Enabling Technologies Chemistry, Biology, and Pre-Clinical Development departments. Previously at Vividion, Dr. Patricelli was SVP, Early Discovery Sciences and led all early drug discovery efforts including target selection and validation, as well as the early development of Vividion’s chemical proteomics platform.

Prior to joining Vividion, Dr. Patricelli served as the Senior Director of Biology at Wellspring Biosciences where he led several drug discovery programs including the KRAS-G12C covalent inhibitor discovery project. From 2000-2012 he led the chemical proteomics platform activities at ActivX Biosciences. He was the first scientist to join ActivX and played a key role in the development of ActivX’s platform technologies, including establishing the KiNativ platform which operated as a successful commercial screening service for more than 15 years.

Dr. Patricelli obtained his B.Sc. in biochemistry from McGill University, and Ph.D. from The Scripps Research Institute as the first graduate student of Vividion’s Co-Founder Dr. Benjamin Cravatt. He is an author or co-author of more than 30 scientific publications and three issued patents.

Jean Bemis joined Vividion in 2017. As Senior Vice President, R&D Operations, Alliances, and Business Development, Ms. Bemis provides strategic oversight of the discovery portfolio and oversees multiple functions including program management, CMC, intellectual property and legal compliance, and site operations. Additionally, she is responsible for establishing and leading strategic alliances and partnerships for the company.

Ms. Bemis brings over 30 years of experience in drug development to Vividion, from early discovery through IND acceptance and clinical study initiation. Prior to joining Vividion she was involved in new company formation at Gene Sciences, Inc., Rodin Therapeutics, and Warp Drive Bio, leading program management and drug development. Prior to that, Ms. Bemis was an early employee of Catabasis Pharmaceuticals, leading the chemistry group from preclinical discovery to CMC campaigns to support clinical studies. In addition to biotherapeutic start-ups, Ms. Bemis’s experience includes driving programs forward at Amgen, GSK, and Wyeth.

Gerry Hernandez serves as the Senior Vice President, Head of Finance since 2023, leading Vividion’s operations related to finance, strategic budgeting, long term planning, financial reporting, procurement, and information technology. Mr. Hernandez joined Vividion in 2018 serving as Controller and then Vice President of Finance. Joining Vividion as its early finance leader, Mr. Hernandez has led cross-functional teams and collaborated with senior management to define, launch, and drive critical strategic business initiatives including private financings, business development, and initial public offering (IPO) readiness in 2021 that pivoted to an acquisition by Bayer.

Mr. Hernandez is an accomplished professional accountant with nearly 20 years of operational and management accounting experience. He first started his career as an auditor at Ernst & Young and then transitioned to working closely with innovative entrepreneurs at both private and public biotechnology companies, leading accounting and cross-functional teams in fast-paced and growth-oriented environments.

Mr. Hernandez earned his B.S. degree in business administration with an emphasis in accounting from Biola University in La Mirada, California.

Laurie Sherman joined Vividion in 2023 as Senior Vice President, Project Management, Project Leadership, and Business Operations. In this role Ms. Sherman provides strategic oversight of Vividion’s development portfolio and oversees project management and project leadership functions. She also supports operations and coordination of Vividion’s Executive Leadership Team.

Ms. Sherman is a clinical research leader who brings over 25 years of development experience to Vividion. She joined the company from Geron Corporation, where she served as Vice President of Project Leadership and Operations, providing leadership and direction for all project management, clinical operations, and clinical development cross-functional efforts. These efforts contributed to the successful FDA approval of imetelstat in low-risk myelodysplastic syndrome. Prior to this, Ms. Sherman was Senior Director, Compound Development Team Leader at Janssen, driving the development and execution strategy for amivantamab in EGFR exon 20 insertion mutated non-small cell lung cancer. During her tenure at Janssen she also worked as a Clinical Scientist Leader and Myeloid Portfolio Leader on multiple assets. Prior to this, Ms. Sherman was at GSK and had multiple functions with increasing responsibilities, including Clinical Research Leader for trametinib in V600E mutated metastatic melanoma, contributing to the successful NDA and MAA approvals. Ms. Sherman’s experience also includes driving programs forward in different capacities at Pfizer, including conduct of clinical pharmacology studies in support of the NDA for sunitinib in renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors.

Ms. Sherman has a B.S. in nursing from the University of Washington School of Nursing.

Alexis McWilliams has served as Vividion’s Vice President, Human Resources, since 2023, providing leadership and guidance to the organization’s HR operations. She joined Vividion in 2017 as Manager, Human Resources and Business Integration. Currently, she collaborates with Vividion’s Executive Leadership Team to define the long-term mission and goals, and identifies ways to support this mission through strategic talent management, including talent acquisition, training and development initiatives, performance management, compensation and benefits design, employee relations, and policy administration.

Prior to joining Vividion, Ms. McWilliams held a variety of senior level positions focused on all aspects of human capital management. Most recently, she worked with a national real estate sales and marketing firm where she oversaw all aspects of its human resources strategy.

Ms. McWilliams graduated from Indiana University with a B.A. in telecommunications.

Phil Worboys, Ph.D., joined Vividion in 2023 to lead the Toxicology, DMPK, and Clinical Pharmacology teams. In this role, he works closely with both Program and Clinical teams to optimize and build Vividion’s capabilities to select and advance pre-clinical candidate molecules into the clinic and through early trials.

Prior to joining Vividion, he was Head of Translational Sciences at Sapient Bio, leading a group discovering and developing small molecule biomarkers. He served as Senior Vice President, Research and Translational Science at Theravance Biopharma from 2008 until 2021, where he was responsible for leading the progression of drug candidates from the discovery stage into human clinical pharmacology and biomarker studies. His functional responsibilities grew to include research (medicinal chemistry and biology/pharmacology), DMPK, toxicology, clinical pharmacology, and project management.

Prior to joining Theravance, Dr. Worboys served as Senior Director, DMPK at Roche Bioscience since 2005 and was Senior Director, DMPK at Pfizer from 2003, after its acquisition of Pharmacia, where he served as an Associate Director, DMPK from 2001 to 2003. He spent the first part of his career in DMPK at Merck Sharp & Dohme in Harlow, United Kingdom, and obtained his Ph.D. degree in pharmaceutics from Manchester University, United Kingdom, and a B.Sc. degree in biochemistry from Imperial College of Science, Technology & Medicine at the University of London.

Dave Bourdet, Ph.D., leads all aspects of Clinical Pharmacology at Vividion. He started his industry career at Chiron Corporation in 2005 as a Scientist and then moved to Roche Palo Alto in 2006, where he worked as a Principal Research Scientist until 2009. In 2009, he joined Theravance Biopharma U.S., Inc. progressing into leading DMPK / clinical and translational pharmacology.

Dr. Bourdet has a Ph.D. in pharmaceutical science with an emphasis in pharmacokinetics from the University of North Carolina at Chapel Hill, which he obtained in 2005. Prior to that, he earned a B.A. in chemistry and history from Duke University in 1996.

Brian Cook, Ph.D., joined Vividion in 2017 and is currently Vice President, Early Discovery Chemistry. In this role, he oversees library build, early chemistry optimization, and lead finding efforts across the portfolio. In addition, he is responsible for analytical chemistry, automation and imaging, and compound management. Prior to this role, Dr. Cook took on increasing responsibility in the Chemistry department, including serving as the Chemistry Lead for one of the first programs at Vividion and taking that project from initial screening hit to development candidate. He contributed to library design and introduced cheminformatic approaches to guide screening deck selection and library analysis.

Prior to joining Vividion, Dr. Cook led Medicinal Chemistry teams at Boehringer Ingelheim Pharmaceuticals for 15 years. During those years, his teams delivered multiple candidate compounds into clinical development.

Dr. Cook received his B.A. in chemistry from Carleton College and his Ph.D. from the University of California at Berkeley. He is an inventor on 19 issued patents and has authored or co-authored 16 scientific papers.

Wendy Hu, Ph.D., joined Vividion in 2023 as Vice President, Head of Toxicology where she manages the toxicology function and drives toxicology strategies to deliver across the portfolio, from target safety assessment for early enablement projects to safety characterization of lead molecules during drug discovery and development. Prior to joining Vividion, she was the Senior Director and Global Lead of Cell and Mechanistic Toxicology at Pfizer.

She has over 20 years of pharmaceutical and biotech industry experience spanning all stages of drug development and has contributed to the safety assessment for numerous programs across multiple disease areas, including oncology, immunology, and rare diseases, utilizing both small and large molecule approaches and novel modalities. She has led limited duration and issue management teams to support nonclinical and clinical safety de-risking, authored multiple INDs and NDAs, and supported successful regulatory interactions.

Dr. Hu received her B.S. in biology from Peking University and Ph.D. in toxicology from Michigan State University. She is also a Diplomate of the American Board of Toxicology since 2007. She has served leadership roles in multiple professional societies and cross-industrial consortia, and was most recently elected as VP of the Drug Discovery Toxicology specialty section of the Society of Toxicology. She has co-authored 40 scientific publications and book chapters, and served on editorial board or as reviewers for top tier toxicology journals.

Maurice Marsini, Ph.D., joined Vividion in 2023 as Vice President, Head of CMC. Maurice is responsible for the chemistry, manufacturing, and controls (CMC) strategy for new molecular entities as they transition from discovery into clinical development and the hands of patients in need.

Prior to joining Vividion, Dr. Marsini spent several years at Gossamer Bio as Senior Director, Head of Process Chemistry within the CMC department. Before joining Gossamer Bio, he was at Receptos/Celgene, where he was responsible for internal and external support of various late-stage development activities and NDA approval for the now marketed Ozanimod. He started his career at Boehringer Ingelheim in Ridgefield, CT.

Dr. Marsini obtained his B.S. in chemistry from Villanova University, Ph.D. in organic chemistry from University of California Santa Barbara, and conducted postdoctoral studies at Princeton University. He is co-author of over 30 academic publications and co-inventor of 12 patents.

David Morris, J.D., joined Vividion in 2024 as Vice President of Legal Affairs, where he oversees high-level legal strategy and general legal matters. With over a decade of experience in the biotech and pharmaceutical sectors, he has developed a robust legal acumen spanning healthcare law, corporate governance, litigation, and contract negotiation.

Most recently, in senior roles at Seagen, Pfizer and Gilead, Mr. Morris guided teams on intricate legal issues related to commercialization, risk mitigation, and compliance. Previously. he held the position of Associate at the law firm Pepper Hamilton LLP (now Troutman Pepper) and earned his J.D. magna cum laude from Rutgers School of Law.

Rick Pagliery, J.D., joined Vividion in 2022 as Vice President, Intellectual Property, and is responsible for managing all aspects of the company’s intellectual property strategy and execution.

Mr. Pagliery brings more than 25 years of experience as an Intellectual Property Attorney to Vividion, including more than 10 years serving as outside counsel with major law firms and more than 15 years as the Head of Intellectual Property at biopharmaceutical companies. He served eight years as Vice President of Intellectual Property at Travere Therapeutics.

Prior to joining Travere, Mr. Pagliery served as Senior Director of Intellectual Property at Achaogen, a biopharmaceutical company focused on developing antibiotics for the treatment of multidrug-resistant bacterial infections and, before then, as Senior Director of Intellectual Property at Neurocrine Biosciences. At Travere, Achaogen, and Neurocrine, Mr. Pagliery was responsible for all aspects of the company’s intellectual property strategy and execution. Mr. Pagliery’s law firm experience includes nationally recognized general practice firms such as Cooley LLP, Paul Hastings, and Brobeck, as well as nationally recognized intellectual property law firms, Lyon & Lyon, and Fitzpatrick Cella.

He holds a J.D. from the University of Florida, an M.S. in chemistry from California State University Long Beach, and an M.S. in microbiology and cell science from the University of Florida. Mr. Pagliery is registered with the United States Patent and Trademark Office and is admitted to practice law in the state of California.

Gabe Simon, Ph.D., joined Vividion in 2017 to lead the Proteomics Platform group. His role involves a dual focus on building and scaling a cutting-edge chemical proteomics screening group, as well as the creation and oversight of a unique and enabling proteo-informatic database called the Data Portal. The proteomics platform group supports nearly all stages of Vividion’s drug discovery efforts and works closely with the early discovery group to identify and prioritize opportunities for development.

Dr. Simon has spent the majority of his scientific career developing proteomics methodologies and novel informatic tools to derive maximum insight from them. Prior to joining Vividion, Dr. Simon was an early employee at Abide Therapeutics where he developed gel- and mass- spectrometry-based screening workflows for the discovery and characterization of covalent serine hydrolase inhibitors that are currently undergoing clinical exploration.

Dr. Simon was a graduate student with Vividion’s co-founder Ben Cravatt at The Scripps Research Institute and performed postdoctoral research with Jeff Gordon at Washington University in St. Louis. He is an author or co-author of more than 30 scientific publications and three issued patents.

Dave Weinstein, Ph.D., joined Vividion in 2017 and has since taken on roles of increasing responsibility. His scientific contributions have resulted from collaborations in compound library design and expansion, establishing a targeted protein degradation platform, and optimizing screening hits to candidates for drug development. As Vice President, Chemistry, Dr. Weinstein is responsible for ensuring that the departments of medicinal and computational chemistry contribute to advancing high quality molecules from across the portfolio of Vividion targets to patients.

Prior to joining Vividion, Dr. Weinstein led medicinal chemistry teams and drug discovery working groups at Bristol-Myers Squibb in Princeton, NJ for 18 years. He and his teams were responsible for delivering multiple candidate compounds into clinical development, including Sotyktu^™ (deucravacitinib), an allosteric TYK2 inhibitor that is now approved for the treatment of plaque psoriasis and is being evaluated for utility in other autoimmune indications.

Dr. Weinstein received his B.S. in chemistry from UCLA and his Ph.D. from Scripps Research. He is an inventor of over 30 issued patents and has co-authored 26 papers.

Stefan Oelrich is a Member of the Board of Management of Bayer AG and President of its Pharmaceuticals division, a position he has held since November 2018.

Prior to joining the company, he was on the Executive Committee of Sanofi, leading its Global Diabetes and Cardiovascular business. During his seven-year tenure, he was also at the helm of Sanofi Germany, Switzerland, and Austria, as well as the diabetes and cardiovascular business units in Europe.

From 1989 to 2011, Dr. Oelrich held various leadership positions in the healthcare business of Bayer AG with extensive international experience spanning Latin America (Argentina, Uruguay), Europe (France, Belgium), and the United States.

Dr. Oelrich is a member of the supervisory board of the University Hospital Charité.

Dr. Cravatt is Professor and Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute. His research group is interested in developing chemical proteomic technologies that enable protein and drug discovery on a global scale, and applying these methods to characterize biochemical pathways that play important roles in human physiology and disease.

Professor Cravatt joined the faculty at The Scripps Research Institute in 1997. In addition to co-founding Vividion, Dr. Cravatt also co-founded Activx Biosciences and Abide Therapeutics. Dr. Cravatt’s honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the RSC Jeremy Knowles Award, the AACR Award for Achievement in Chemistry in Cancer Research, the Wolf Prize in Chemistry, and memberships in the National Academies of Medicine and Sciences.

Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in biological sciences and a B.A. in history. He then received a Ph.D. from The Scripps Research Institute in 1996.

Tom Daniel, M.D., has more than 20 years of experience leading and building research and development organizations, as well as leading investments in new companies at the forefront of innovative application of science to healthcare. Recently, he served as a Venture Partner at ARCH Venture Partners for five years following a decade as President of Global Research and Early Development at Celgene Corporation. He previously served in senior leadership roles at AmbRx, Amgen, and Immunex. Dr. Daniel was formerly a Director at Juno Therapeutics, Epizyme, Sana Biotechnologies, Larimar Therapeutics, and Vir Biotechnology. He currently serves as Board Chair at LocanaBio, Gate Therapeutics, and Trotana Therapeutics, and is Director at Gossamer Bio, Magenta Therapeutics, Aspen Biosciences, and Mozart Therapeutics. He chairs the Board of Managers for Life Science Cares-San Diego, serves as a Trustee at Reed College, is Director and Chair of the Board of Overseers at Scripps Research, and acts as Senior Advisor to several private biotechnology companies.

A nephrologist and former academic investigator, Dr. Daniel was previously C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University. Dr. Daniel received his M.D. from the University of Texas, Southwestern, trained in molecular genetics at UTSW, and completed his residency in internal medicine at Massachusetts General Hospital.

Richard Heyman, Ph.D., is a scientist and entrepreneur with more than 25 years of experience in co-founding and building biotech and life science companies. He is the Co-Founder and Chairman of ORIC Pharmaceuticals, which is developing drugs to overcome resistance in cancer. Dr. Heyman most recently served as Chairman of both Vividion Therapeutics, which was purchased in August 2021 by Bayer AG, and Amunix Pharmaceuticals, which was purchased by Sanofi in December 2021. Previously, Dr. Heyman was the Co-Founder and CEO of Aragon and Seragon Pharmaceuticals, which focused on therapeutics targeting hormone dependent cancers; J&J purchased Aragon in 2013 and Genentech purchased Seragon one year later. He has been involved in the discovery and development of multiple therapeutic agents approved by the FDA, including the prostate cancer drug, ERLEADA®. Dr. Heyman is a Venture Partner for ARCH Ventures and serves as Chairman of PMV Pharma and RayzeBio, as well as serving on the Board of Directors of Enliven Therapeutics. In addition to his corporate experience, Dr. Heyman is Vice Chair of the Board of Trustees at the Salk Institute, on the Board Foundation for the AACR, the Board of Directors at the UCSD Moores Cancer Center, and a Founding Member of both Life Science Cares, San Diego and Curebound. He has won numerous awards including Ernst and Young San Diego Regional Entrepreneur of the Year, Connect Hall of Fame Award, and the Endocrine Society Outstanding Innovation Award.

Earlier in his career he trained as an NIH postdoctoral fellow and staff scientist at the Salk Institute. Dr. Heyman is the author or inventor on more than 125 publications and patents.

Olivier Mauroy-Bressier is the Chief Financial Officer at Bayer Pharmaceuticals, having assumed his role in October 2022. He joined Bayer through the Aventis Crop Science acquisition in 2001, and held increasing responsibilities in the areas of finance, strategic planning, mergers, and acquisitions and transfer price office for Bayer Crop Science in the US and the headquarters in Germany. In 2009, he assumed the CFO role for Bayer Group in France. After heading the Global Controlling and Business Analytics organization for Bayer Consumer Care between 2014 and 2016 in the US, Mr. Mauroy-Bressier relocated to Basel, Switzerland to lead the establishment of Bayer Consumer Health as the divisional CFO in 2016, coordinating and overseeing the subsequent turn-around of the business until end of 2019. Before taking his current role, Mr. Mauroy-Bressier served as Head of Internal Audit & Risk Management for the Bayer Group, dedicated to safeguard and strengthen Bayer’s license to operate.

Mr. Mauroy-Bressier holds a M.S. in corporate finance from EDHEC Business School, France.

Frank Poschen is the Global HR Head of Global HR Pharmaceuticals at Bayer, based in Berlin, Germany. In his role, he is dedicated to unleashing human potential within a highly innovative, fluid, and adaptable ecosystem, and is a key member of the PH Leadership Team of Bayer Pharmaceuticals. With over two decades of experience in HR, Mr. Poschen has spent nearly a decade at Bayer in various leadership roles, including Global Head of HR Business Partnering for R&D, Marketing, and Global Culture and Change Lead. Prior to joining Bayer, he worked for almost 15 years at Grünenthal, in mid-sized & start-up environments.

Mr. Poschen holds an M.S. in European labor sciences from Warwick Business School in the UK and an M.S. in economics from Universität Trier in Germany. He is also a certified coach and organizational developer.

Christian Rommel, Ph.D., became Global Head of Research & Development of Bayer Pharmaceuticals in February 2021. He joined Bayer from Roche, where he was most recently Senior Vice President, Global Head of Oncology, Pharma Research and Early Development (pRED). Dr. Rommel also served at Amgen as Vice President of External Research and Development. Before that role, he was Amgen’s Vice President, Research Oncology. Previously, he served as Chief Scientific Officer of Intellikine, a private biotech company based in San Diego, from its inception to acquisition by Takeda.

Earlier in his career, Dr. Rommel was Head of Target Research at Merck-Serono in Geneva, Switzerland. He also worked as a scientist on the team of George Yancopoulos at Regeneron Pharmaceuticals, New York.

Dr. Rommel is a member of the board of directors of Asklepios BioPharmaceutical (AskBio) and BlueRock Therapeutics. He is a lecturer of biotechnology at the ETH Zurich, Switzerland. Dr. Rommel has authored more than 70 publications, including papers in Science and Nature and is an inventor or co-inventor of 18 patents.

Dr. Rommel received his Ph.D. in molecular oncology from the Max Planck Institute in Berlin, Germany and the Institute of Medical Virology at the University of Zurich, Switzerland.

Christine Roth is a highly accomplished pharma executive recognized for building purpose-driven oncology organizations that accelerate delivery of innovative therapies. In her three decades of experience, she has played key roles in the development and launches of the first immuno-oncology therapy, the first intentionally designed targeted therapy combination, and multiple new drug classes.

Ms. Roth is a member of the Pharmaceuticals Executive Committee of Bayer AG, where she is the Executive Vice President of the Oncology Strategic Business Unit. She joined Bayer in early 2022 after leading the rebuild of the oncology business at GSK, including the acquisition of TESARO. Prior to this, she held country and global leadership positions in oncology, cardiovascular, metabolic, and infectious disease therapy areas at Novartis and Bristol-Myers Squibb.

Benjamin Cravatt, Ph.D., is Professor and Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute. His research group is interested in developing chemical proteomic technologies that enable protein and drug discovery on a global scale and applying these methods to characterize biochemical pathways that play important roles in human physiology and disease.

Dr. Cravatt joined the faculty at The Scripps Research Institute in 1997. In addition to co-founding Vividion, Dr. Cravatt also co-founded Activx Biosciences and Abide Therapeutics. Dr. Cravatt’s honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the RSC Jeremy Knowles Award, the AACR Award for Achievement in Chemistry in Cancer Research, the Wolf Prize in Chemistry, and memberships in the National Academies of Medicine and Sciences.

Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the biological sciences and a B.A. in history. He then received a Ph.D. from The Scripps Research Institute in 1996.

Phil Baran received his B.S. in chemistry from New York University in 1997, his Ph.D. at The Scripps Research Institute in 2001, and from 2001-2003, he was an NIH-Postdoctoral Fellow at Harvard. Dr. Baran began his independent career at Scripps in the summer of 2003. He currently holds the Darlene Shiley Chair in Chemistry. He has published over 180 scientific articles and has been the recipient of several ACS awards, such as the Corey (2015), Pure Chemistry (2010), Fresenius (2006), and Nobel Laureate Signature (2003). He also has several international distinctions such as the Hirata Gold Medal and Mukaiyama Prize (Japan), the RSC award in Synthesis (UK), and the Sackler Prize (Israel). In 2013 he was named a MacArthur Foundation Fellow, in 2015 he was elected to the American Academy of Arts and Sciences, and in 2016 he was awarded the Blavatnik National Award.

Dr. Baran has delivered hundreds of lectures around the world, and consults for numerous companies such as Bristol-Myers Squibb (since late 2005), Boehringer-Ingelheim, AstraZeneca, DuPont, and TEVA, and is a Scientific Advisory Board Member for Eisai, Abide Therapeutics, and AsymChem. In 2016, he was appointed as an Associate Editor for the Journal of the American Chemical Society. He co-founded Sirenas Marine Discovery (2012) and Vividion Therapeutics (2016), and in 2013, he co-authored The Portable Chemist’s Consultant, an interactive book published on the iBooks store along with his graduate class in Heterocyclic Chemistry.

Jin-Quan Yu, Ph.D., received his B.S. in chemistry at East China Normal University, where he worked with Professor Li-Xin Dai and Professor Bi-Qi Wu as a visiting student at Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 1987. Following a one-year course study at Shanghai Institute of Organic Chemistry, Dr. Yu went to Guangzhou Institute of Chemistry, Chinese Academy of Sciences to study terpene chemistry and heterogeneous catalysis under the supervision of Professor Shu-De Xiao, and obtained his M.S. in 1990. He stayed on as a research associate for four years and went to Cambridge University for his doctoral studies under the supervision of Dr. J.B. Spencer, where he studied biosynthesis and the mechanistic details of the hydrometallation step in asymmetric hydrogenation. Dr. Yu was elected as a Junior Research Fellow of St John’s College, Cambridge University in 1998. From 2001-2002, Jin-Quan worked on Pd-catalyzed allylic oxidation as a postdoctoral fellow at Harvard University in the laboratories of Professor E. J. Corey. He returned to Cambridge University in 2002 and was appointed as a University Royal Society Research Fellow in 2003 to start his independent research towards developing asymmetric C–H insertion reactions. In 2004, he moved to Brandeis University as an Assistant Professor of Chemistry. He joined The Scripps Research Institute as an Associate Professor in 2007 and became a full Professor in August 2010. He was appointed as the Frank and Bertha Hupp Professor of Chemistry at The Scripps Research Institute in 2012. He received the Mukaiyama Award in 2012, the Raymond and Beverly Sackler Prize in Physical Sciences in 2013, the Elias J. Corey Award in 2014, and the MacArthur Fellowship in 2016.